Cargando…

Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study

Chronic traumatic brain injury (TBI) can cause permanent disability and thereby negatively affect patients, families, and society. Currently, there is no effective treatment for patients with chronic TBI. One possible option is granulocyte colony-stimulating factor (G-CSF), which has potential neuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Tsung-Lang, Wang, Ya-Jung, Chang, Tze-Wei, Lin, Shinn-Zong, Tsai, Sheng-Tzung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615826/
https://www.ncbi.nlm.nih.gov/pubmed/34827440
http://dx.doi.org/10.3390/brainsci11111441
_version_ 1784604199495925760
author Chiu, Tsung-Lang
Wang, Ya-Jung
Chang, Tze-Wei
Lin, Shinn-Zong
Tsai, Sheng-Tzung
author_facet Chiu, Tsung-Lang
Wang, Ya-Jung
Chang, Tze-Wei
Lin, Shinn-Zong
Tsai, Sheng-Tzung
author_sort Chiu, Tsung-Lang
collection PubMed
description Chronic traumatic brain injury (TBI) can cause permanent disability and thereby negatively affect patients, families, and society. Currently, there is no effective treatment for patients with chronic TBI. One possible option is granulocyte colony-stimulating factor (G-CSF), which has potential neuroregenerative and neuroprotective effects through its ability to mobilize hematopoietic stem cells and increase neurogenic growth factor levels. Previous studies have shown that G-CSF administration is safe for patients with neurological diseases such as stroke and dementia. The present study aimed to explore the safety and efficacy of G-CSF use in patients with chronic TBI. Methods: 38 patients with chronic TBI were administered 3-day rounds of G-CSF (10 μg/kg per day) once a month for 6 months. These patients were clinically evaluated using the modified Rankin scale (mRS) and Karnofsky Performance Score (KPS). Laboratory measures of the leucocyte counts and differential count percentage were also assessed. Results: At the 6-month follow-up, further assessment showed that patients tolerated the treatment well with only mild and transient side effects being observed. Further clinical evaluation showed significant improvements in mRS and KPS after G-CSF treatment. Laboratory results also confirmed the action of the medication, with increased leukocytosis and band forms. Conclusions: The results suggest that 6-month chronic G-CSF treatment is safe for patients with chronic TBI and may provide clinical benefits and neurological improvements. The adverse effects of the treatment, however, are transient and usually tolerable. Thus, these preliminary findings suggest that future clinical trials of G-CSF use in patients with chronic TBI are warranted.
format Online
Article
Text
id pubmed-8615826
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86158262021-11-26 Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study Chiu, Tsung-Lang Wang, Ya-Jung Chang, Tze-Wei Lin, Shinn-Zong Tsai, Sheng-Tzung Brain Sci Article Chronic traumatic brain injury (TBI) can cause permanent disability and thereby negatively affect patients, families, and society. Currently, there is no effective treatment for patients with chronic TBI. One possible option is granulocyte colony-stimulating factor (G-CSF), which has potential neuroregenerative and neuroprotective effects through its ability to mobilize hematopoietic stem cells and increase neurogenic growth factor levels. Previous studies have shown that G-CSF administration is safe for patients with neurological diseases such as stroke and dementia. The present study aimed to explore the safety and efficacy of G-CSF use in patients with chronic TBI. Methods: 38 patients with chronic TBI were administered 3-day rounds of G-CSF (10 μg/kg per day) once a month for 6 months. These patients were clinically evaluated using the modified Rankin scale (mRS) and Karnofsky Performance Score (KPS). Laboratory measures of the leucocyte counts and differential count percentage were also assessed. Results: At the 6-month follow-up, further assessment showed that patients tolerated the treatment well with only mild and transient side effects being observed. Further clinical evaluation showed significant improvements in mRS and KPS after G-CSF treatment. Laboratory results also confirmed the action of the medication, with increased leukocytosis and band forms. Conclusions: The results suggest that 6-month chronic G-CSF treatment is safe for patients with chronic TBI and may provide clinical benefits and neurological improvements. The adverse effects of the treatment, however, are transient and usually tolerable. Thus, these preliminary findings suggest that future clinical trials of G-CSF use in patients with chronic TBI are warranted. MDPI 2021-10-29 /pmc/articles/PMC8615826/ /pubmed/34827440 http://dx.doi.org/10.3390/brainsci11111441 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chiu, Tsung-Lang
Wang, Ya-Jung
Chang, Tze-Wei
Lin, Shinn-Zong
Tsai, Sheng-Tzung
Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
title Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
title_full Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
title_fullStr Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
title_full_unstemmed Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
title_short Granulocyte Colony-Stimulating Factor for Treatment of Patients with Chronic Traumatic Brain Injury: A Preliminary Pre-Post Study
title_sort granulocyte colony-stimulating factor for treatment of patients with chronic traumatic brain injury: a preliminary pre-post study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615826/
https://www.ncbi.nlm.nih.gov/pubmed/34827440
http://dx.doi.org/10.3390/brainsci11111441
work_keys_str_mv AT chiutsunglang granulocytecolonystimulatingfactorfortreatmentofpatientswithchronictraumaticbraininjuryapreliminaryprepoststudy
AT wangyajung granulocytecolonystimulatingfactorfortreatmentofpatientswithchronictraumaticbraininjuryapreliminaryprepoststudy
AT changtzewei granulocytecolonystimulatingfactorfortreatmentofpatientswithchronictraumaticbraininjuryapreliminaryprepoststudy
AT linshinnzong granulocytecolonystimulatingfactorfortreatmentofpatientswithchronictraumaticbraininjuryapreliminaryprepoststudy
AT tsaishengtzung granulocytecolonystimulatingfactorfortreatmentofpatientswithchronictraumaticbraininjuryapreliminaryprepoststudy